AZ's Imfinzi reduces the risk of death by 32% in non-progressing Phase III NSCLC trial

AstraZeneca plc (LSE:AZN; NYSE:AZN) said PD-L1 inhibitor Imfinzi durvalumab reduced the risk of death by 32% in the Phase III PACIFIC trial to treat locally advanced, unresectable non-small

Read the full 289 word article

User Sign In